UNITED ~~STATES~~STATESSECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549



	FORM 8-K

CURRENT ~~REPORT~~REPORTPursuant ~~PURSUANT~~to Section 13 or 15(d) of the Securities Exchange Act of 1934

TODate ~~SECTION~~of 13Report ~~OR 15~~(DDate of Earliest Event Reported): OFMarch ~~THE~~25, 2019

~~SECURITIES~~SYDYS ~~EXCHANGE ACT OF 1934~~CORPORATION

~~Date~~ ~~of report~~ (~~Date~~Exact name of ~~earliest~~registrant ~~event~~as ~~reported):~~specified ~~May~~in ~~10, 2016~~charter)

Sydys Corporation




Nevada	333-120893	98-0418961
(State or Other Jurisdiction of		(I.R.S. Employer
Incorporation)	(Commission File Number)	Identification No.)

~~(Exact~~135 ~~name~~East of57thStreet, ~~small~~24 ~~business~~th ~~issuer~~FloorNew asYork, ~~specified~~New inYork ~~its charter)~~10022

Nevada	98-041896
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)

(Address and Zip Code of Principal Executive Offices)

~~135 East 57th Street, 24th Floor, New York, NY 10022~~ (~~Address of principal executive offices~~646) 406-6243

(~~646) 406-6243 (Issuer~~Registrant’s ~~telephone~~Telephone ~~number~~Number, including area code)

~~2811 East Madison, Suite 300, Seattle, Washington 98112~~ n/a(Former ~~name~~Name or ~~former~~Former ~~address~~Address, if ~~changed~~Changed ~~since~~Since ~~last~~Last ~~report~~Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[o ] Written communications pursuant to Rule 425 under the Securities Act (17 ~~CFR~~CF R. 230.425)

[o ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR. 240.~~14a~~14-1212a)

[o ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR. 240.14d-2(b))

[o ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR. 240.~~13e~~13-4e4(c))

~~Section~~Indicate 1by –check ~~Registrant’s~~mark ~~Business~~whether ~~and~~the ~~Operations~~registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

~~Item~~If 1an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.01 ☐

~~Entry~~Item ~~Into~~8.01 aOther ~~Material Definitive Agreement~~Events.

~~Change~~On inMarch ~~Control~~25, 2019, Sydys Corporation (the “Company”) issued a press release announcing that it has filed a Form 15, Certification and Notice of Termination of Registration Under Section 12(g) of the Securities Exchange Act of 1934 or Suspension of Duty to File Reports Under Sections 12 and 15(d) of the Securities Exchange Act of 1934. The press release, dated March 18, 2019, is attached to this Report as Exhibit 99.1 and incorporated herein by reference.

OnItem ~~May 10, 2016, we issued 17,220,000 shares of our newly designated Series A Preferred Stock to Mr~~9.01 ~~Joseph~~Financial ~~Hernandez. In~~Statements ~~exchange, Mr. Hernandez delivered a promissory note in the amount of $210,000 to our former majority shareholder~~ and ~~CEO, Michael Warsinske~~Exhibits. In turn, and in exchange for the note from Mr. Hernandez, Mr. Warsinkse executed a Release and Indemnity Agreement under which he released us of $415,456.78 in total liabilities owed to him. In addition, Mr. Warsinske agreed to and indemnify us from any liabilities arising prior to the transaction with exception of certain specified liabilities totaling $20,159.57.

~~Our newly designated class of Series A Preferred Stock consists of 19,500,000 shares, par value $0.001 per share. Series A Preferred Stock is convertible to common stock at a rate of two~~ (2d) ~~shares of common stock for every one (1) share of Series A Preferred Stock~~Exhibits. Series A Preferred Stock votes together with the common stock on an as-if-converted basis. Series A Preferred Stock has no preferred dividend rights and with respect to rights on liquidation, winding up and dissolution, will rank pari passu with the class of common stock. As a result of these transactions, a change in control of the company occurred on May 10, 2016.

In concert with the change in control transaction described above and as a significant feature of an overall reorganization of our capital structure, our Board of Directors and a majority of our shareholders have approved a reverse split of all outstanding shares of our common stock in a ratio of 1 for 7.5. The reverse split is expected to take effect twenty days after our mailing of a definitive Schedule 14C to shareholders, and upon completion of the mandatory review process at FINRA. Immediately following the reverse split, we will have approximately 1,600,000 shares of common stock issued and outstanding.


Exhibit No.		Description

99.1		Press Release dated March 25, 2019

Following the actions described above, our CEO and Director, Michael Warsinske, and our CFO and Director, Mark Noffke resigned from their executive officer positions and appointed Joseph Hernandez as our CEO, CFO, and Executive Chairman. In addition, Mr. Warsinske and Mr. Noffke appointed Joseph Hernandez to our Board of Directors and resigned from the board effective ten (10) days after mailing to shareholders of our Schedule 14f-1 regarding the change in our board. SIGNATURES

~~Agreement~~In accordance with ~~Prima~~the ~~Biomed~~requirements ~~Ltd~~of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 25th day of March 2019.

OnSYDYS ~~May~~CORPORATION ~~11, 2016, we entered into a Sub-License, License, and Asset Purchase Agreement~~ (~~the “Agreement”~~Registrant) ~~with~~BY: Prima Biomed Ltd., an Australian corporation (“Prima”). Under the Agreement, we have obtained a worldwide exclusive sub-license to certain patents and certain intellectual property and other assets related to CVacTM, a therapy based on ex vivo pulsing of dendritic cells or monocytes with the mannosylated fusion protein. CVac™ therapy is a personalized immunocellular therapeutic that has been investigated for the treatment of epithelial cancers. CVac™ stimulates the patient’/s/ ~~own~~Joseph ~~immune~~Hernandez ~~system~~Joseph toHernandez ~~target~~President and ~~destroy~~Chief ~~tumours.~~Executive It has been investigated in multiple Phase I and Phase II studies with positive results. In addition to the exclusive sub-license to CVac™ intellectual property, we have also obtained a non-exclusive sublicense and license to all know-how related to CVac™ and have acquired certain assets, including Prima’s inventory of CVac™ products and components, certain machinery and equipment, certain contract rights, and documents and records.Officer

InExhibit ~~consideration for the sub-license and related items acquired under the Agreement, we have agreed to issue Prima 1,980,000 shares of Series A Preferred Stock~~99. Following the effectiveness of the reverse split of common stock discussed above, this will represent 9.9% of our total issued and outstanding capital stock on a fully converted basis. Prima’s equity position shall be non-dilutable until such time as we have closed an equity financing in the minimum amount of $20,000,000. In addition, for so long as Prima holds more than 5% of our outstanding capital stock, it shall be entitled to appoint one member to our board of directors. 1

~~The~~Sydys ~~Agreement~~Corporation ~~requires~~Announces usFiling ~~to make certain payments to Prima upon the achievement~~ of ~~various~~Form ~~developmental~~15 ~~milestones. In addition, we are required~~ to ~~make~~Deregister ~~additional~~its ~~payments~~Common ~~upon~~Stock ~~the achievement of certain sales milestones.~~

~~The~~New ~~foregoing~~York, ~~description~~NY. ofMarch 25, 2019 – Sydys Corporation (OTCPK: SYYC, the ~~Agreement~~“Company”), ~~does~~globally ~~not~~active ~~purport~~biotechnology tocompany bedeveloping ~~complete~~immuno-oncology products, today announced that on March 25, 2019, the Company voluntarily filed a Form 15 with the United States Securities and isExchange ~~qualified~~Commission in(the “Commission” or “SEC”) to voluntarily deregister its ~~entirety~~common bystock ~~reference~~and suspend its reporting obligations under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Company expects deregistration to become effective within 90 days of the ~~complete~~filing ~~text~~of the Form 15. As a result of the ~~Agreement~~Form 15 filing, ~~which~~the isCompany's ~~filed~~obligations asto ~~Exhibit~~file with the SEC certain periodic reports and forms, including Forms 10.2-K, ~~hereto~~10-Q and ~~incorporated~~8-K, ~~herein~~will bybe ~~reference~~suspended as of the date of the filing of the Form 15.

~~Section~~The 3Company's –Board ~~Securities~~of Directors carefully considered the advantages and ~~Trading~~disadvantages ~~Markets~~of deregistration before approving the filing of the Form 15, including such factors as the high costs of filing and preparing periodic reports for the SEC, the increased outside accounting, audit, legal and other expenses and costs associated with being a public reporting company, the burdens placed on management to comply with the Exchange Act reporting requirements, and the limited liquidity for the Company's common stock.

~~Item~~The 3Company believes that following the filing of the Form 15 its shares of common stock will continue to be quoted on OTC Pink Marketplace, although there can be no assurances that a broker will continue to make a market in the Company's common stock or that trading will continue in the future.~~02.~~

~~Unregistered~~“We ~~Sales~~believe that by removing the expense burden that accompanies the SEC reporting requirements, it will allow us to focus our time and resources on building long-term value in the Company,” said Joseph Hernandez Executive Chairman of ~~Equity~~Sydys ~~Securities~~Corporation.

InAbout ~~connection~~Sydys ~~with~~CorporationSydys ~~the~~Corp ~~acquisition~~is ofa ~~controlling~~globally ~~interest~~active bybiotechnology ~~Mr.~~company ~~Hernadez~~developing ~~and~~immuno-oncology ~~the~~products ~~Agreement~~including ~~with~~an ~~Prima~~autologous ~~Biomed,~~dendritic ~~Ltd.,~~cell asimmunotherapy ~~discussed~~that ~~above,~~recently wecompleted ~~have~~Phase ~~issued~~II atrials ~~total~~for ofovarian ~~19,200,000~~cancer ~~shares~~generating ofclinically ~~our~~meaningful ~~newly-designated~~progression ~~Series~~free Asurvival ~~Preferred~~(PFS) ~~Stock.~~and ~~These~~overall ~~shares~~survival ~~of preferred stock were issued in reliance on the exemption from registration afforded by Section 4~~(2OS) ~~of the Securities Act~~data. We For ~~did~~more ~~not~~information, ~~engage~~please invisit ~~any general solicitation or advertising with respect to the issuance of these shares~~www. sydyscorp.com.

~~Section~~FORWARD 5LOOKING ~~– Corporate Governance and Management~~STATEMENTS

~~Item~~Certain 5statements contained in this news release regarding matters that are not historical facts may be forward-looking statements.01 Because such forward-looking statements include risks and uncertainties, actual results may differ materially from those expressed in or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company’s ability to realize anticipated cost savings from its deregistration, the ability to timely and effectively implement its future business plans, and any adverse effects on share price and liquidity following the Company’s deregistration. Other factors not currently anticipated may also materially and adversely affect the Company’s results of operations, financial position and cash flows. There can be no assurance that future results will meet expectation. While the Company believes that the forward-looking statements in this news release are reasonable, the reader should not place undue reliance on any forward-looking statement. In addition, these statements speak only as of the date made. The Company does not undertake, and expressly disclaims any obligation to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

~~Changes~~Contact inInformation:Betty ~~Control~~Rose ~~of Registrant~~(investors)brose@embertx.com

Reference is made to the disclosure set forth under Item 1.01 of this Current Report on Form 8-K, which disclosure is incorporated herein by reference.

Item 5.02.

Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

As discussed above, our CEO and Director, Michael Warsinske, and our CFO and Director, Mark Noffke resigned from their executive officer positions and appointed Joseph Hernandez as our CEO, CFO, and Executive Chairman effective May 10, 2016. In addition, Mr. Warsinske and Mr. Noffke appointed Joseph Hernandez to our Board of Directors and resigned from the board effective ten (10) days after mailing to shareholders of our Schedule 14f-1 regarding the change in our board.

Joseph Hernandez, M.S., MBA, is currently the Executive Chairman and a member of the Board of Directors of Ember Therapeutics, Inc. Mr. Hernandez is the founder of several biotechnology companies, including Microlin Bio, Inc., a biotechnology company focusing on microRNA diagnostics and therapeutics in oncology, where he currently serves as Executive Chairman and Chief Executive Officer; Prolias Technologies, Inc., a molecular diagnostics company focusing on thyroid cancer, where he has served as its Chairman since March 2010 and a director since September 2010; and Innovative Biosensors, Inc., a MIT-based technology company that develops, manufactures and markets rapid pathogen detection and diagnostic systems comprised of biosensors, where he served as President and Chief Executive Officer from 2003 until 2009. From July 2010 to March 2012, Mr. Hernandez also served as President and Chief Executive Officer of Signal Genetics, LLC, a privately-held company focused on oncology and the development of innovative diagnostic services. Mr. Hernandez has held numerous business development and marketing roles, having served in such roles at Digene Corporation (which has since been acquired by Qiagen), a molecular diagnostics company that develops, manufactures and markets gene-based testing systems for the screening, monitoring and diagnosis of certain human diseases, such as women’s cancers and infectious diseases, from 2001 to 2003, and at Affymetrix, Inc., a publicly-held Silicon Valley biotech company that develops DNA microarrays, from 2000 to 2001. From 1998 to 2000, Mr. Hernandez worked in sales and marketing for the publicly-held pharmaceutical company Merck. Mr. Hernandez is a member of the board of directors of MdBIO, a life science industry association based in the Mid-Atlantic region, and a member of the board of directors of Shady Grove Hospital. Mr. Hernandez holds an M.S. in Microbiology and Molecular Genetics from the University of Florida and a B.S. in Neuroscience from the University of Florida.

Mr. Hernandez has not had any material direct or indirect interest in any of our transactions or proposed transactions over the last two years. At this time, we do not have a written employment agreement or other formal compensation agreement with Mr. Hernandez.

Item 5.03

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

As discussed in Item 1.01, above, we have designated a new class of preferred stock. Our newly designated class of Series A Preferred Stock consists of 19,500,000 shares, par value $0.001 per share. Series A Preferred Stock is convertible to common stock at a rate of two (2) shares of common stock for every one (1) share of Series A Preferred Stock. Series A Preferred Stock votes together with the common stock on an as-if-converted basis. Series A Preferred Stock has no preferred dividend rights and with respect to rights on liquidation, winding up and dissolution, will rank pari passu with the class of common stock.

Section 9 – Financial Statements and Exhibits

Item 9.01.

Financial Statements and Exhibits

Exhibit No.	Description
3.1	Certificate of Designation of Series A Preferred Stock
10.1	Subscription Agreement with Joseph Hernandez
10.2	Sub-License, License, and Asset Purchase Agreement (the “Agreement”) with Prima Biomed Ltd.*

*Document has been redacted in part; the company will request confidential treatment

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Sydys Corporation

Joseph Hernandez

Executive Chairman and CEO

Date: May 12, 2016

Filing Compare · SYDYS CORP